Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.
Thirty-two acutely psychotic, male schizophrenic patients received raclopride, at 2, 6, or 12 mg/day, or haloperidol, 15 mg/day for 4 weeks after randomized, double-blind assignment. Twenty-six patients, including 19 who had been assigned one of the three doses of raclopride, completed the study. Raclopride, particularly at 12 mg/day, increased CSF homovanillic acid (HVA) at 4 weeks, and plasma HVA at 2 days, of treatment. The clinical response to raclopride was significantly correlated with plasma raclopride concentrations and baseline plasma HVA concentrations. Although raclopride is a substituted benzamide with atypical properties in animals, these results suggest that the doses of raclopride required for clinical efficacy and elevation of clinical indices of brain dopamine turnover are similar.
Csernansky
J G
JG
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110.
Newcomer
J W
JW
Jackson
K
K
Lombrozo
L
L
Faull
K F
KF
Zipursky
R
R
Pfefferbaum
A
A
Faustman
W O
WO
D000328:Adult; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D004311:Double-Blind Method; D006719:Homovanillic Acid / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood / Q000134:cerebrospinal fluid; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000097:blood / Q000134:cerebrospinal fluid; D011569:Psychiatric Status Rating Scales; D020891:Raclopride; D012457:Salicylamides / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D018492:Dopamine Antagonists; D012457:Salicylamides; D020891:Raclopride; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D006719:Homovanillic Acid